These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26717378)

  • 21. Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients.
    Lafarge L; Khayi F; Bel-Kamel A; Charhon N; Sarfati L; Falquet B; Ducher M; Bourguignon L
    Drugs Aging; 2018 Jun; 35(6):569-574. PubMed ID: 29882202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Bleeding secondary to vitamin K antagonist treatment: adaptation of the International Normalized Ratio (INR) determination during high hypertriglyceridemia].
    Miot S; Marteau AT; Simard G; Lavigne C
    Rev Med Interne; 2010 Jan; 31(1):60-2. PubMed ID: 19201067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors of vitamin K antagonist overcoagulation. A case-control study in unselected patients referred to an emergency department.
    Cadiou G; Varin R; Levesque H; Grassi V; Benichou J; Tiret I; Dieu B; Lecam-Duchez V; Borg JY; Muller JM; Benhamou Y; Marie I
    Thromb Haemost; 2008 Oct; 100(4):685-92. PubMed ID: 18841293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study.
    Stage TB; Pottegård A; Henriksen DP; Christensen MM; Højlund K; Brøsen K; Damkier P
    J Thromb Haemost; 2016 Jan; 14(1):129-33. PubMed ID: 26559049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
    Coppens M; Synhorst D; Eikelboom JW; Yusuf S; Shestakovska O; Connolly SJ
    Eur Heart J; 2014 Jul; 35(28):1856-63. PubMed ID: 24569032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
    Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Decisional algorithm to prescribe vitamin K antagonist in geriatric patients with atrial fibrillation].
    Sibai MS; Bellarbre F; Ghazali N; Bureau ML; Priner M; Ingrand P; Paccalin M
    Geriatr Psychol Neuropsychiatr Vieil; 2014 Mar; 12(1):20-4. PubMed ID: 24647235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome.
    Halbritter K; Beyer-Westendorf J; Nowotny J; Pannach S; Kuhlisch E; Schellong SM
    J Thromb Haemost; 2013 Apr; 11(4):651-9. PubMed ID: 23347087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis.
    Vazquez FJ; Gonzalez JP; LeGal G; Carrier M; Gándara E
    Thromb Res; 2016 Feb; 138():1-6. PubMed ID: 26826501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF.
    Goto S; Goto S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Haas S; Parkhomenko A; Oto A; Misselwitz F; Turpie AGG; Verheugt FWA; Fox KAA; Gersh BJ; Kakkar AK
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):301-309. PubMed ID: 31821482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.
    De Vriese AS; Caluwé R; Pyfferoen L; De Bacquer D; De Boeck K; Delanote J; De Surgeloose D; Van Hoenacker P; Van Vlem B; Verbeke F
    J Am Soc Nephrol; 2020 Jan; 31(1):186-196. PubMed ID: 31704740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Frequency of use of oral vitamin K antagonists in patients with atrial fibrillation and cognitive function disturbances].
    Gorzelak P; Zyzak S; Krewko Ł; Mozdzan M; Broncel M
    Pol Merkur Lekarski; 2014 May; 36(215):302-6. PubMed ID: 24964505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding.
    Imberti D; Magnacavallo A; Dentali F; Condoleo E; Gallerani M; Benedetti R; Ageno W
    J Thromb Thrombolysis; 2013 Jul; 36(1):102-8. PubMed ID: 23054464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
    Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
    Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Casamira N; García-Camarero T; Montoro-Ronsano JB; Veiga G; Del Blanco BG; De La Torre JM; Gordon B; García-Dorado D; Sambola A
    Am J Med Sci; 2019 Aug; 358(2):95-103. PubMed ID: 31176420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Incidence of complications of antithrombotic treatment in patients with atrial fibrillation].
    Novaković Anucin S; Gnip S; Canak V; Radović P; Kovacev J; Mitić G
    Med Pregl; 2013; 66(11-12):470-5. PubMed ID: 24575635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
    Lamberts M; Olesen JB; Ruwald MH; Hansen CM; Karasoy D; Kristensen SL; Køber L; Torp-Pedersen C; Gislason GH; Hansen ML
    Circulation; 2012 Sep; 126(10):1185-93. PubMed ID: 22869839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.